Objective: To evaluate the clinical medication safety of cefazolin and cefuroxime for injection

so as to provide references for rational selection of prophylactic antibiotics during perioperative period. Methods: The adverse event (ADE) report data of cefazolin and cefuroxime were extracted from the domestic and foreign electronic literature databases

the US Food and Drug Administration’s (FDA) Adverse Event Reporting System (FAERS)

the WHO Global Case Safety Pathology Report Database (VigiBase) and the safety information released by the National Medical Products Administration (NMPA). The expert consultation method and analytic hierarchy process were used to calculate the comprehensive weight to evaluate the medication safety of cefazolin and cefuroxime. Results: Among the cases reported in the literature

the number of ADE reports of cefazolin was greater than that of cefuroxime; in FAERS and VigiBase databases

the incidence of cefuroxime ADE was significantly higher than that of cefazolin ADE; by building a hierarchical model

expert scoring

and calculating the comprehensive weight

cefazolin (0. 625

7) was superior to cefuroxime (0. 374

3). Conclusion: Based on this study

cefazolin has more advantages in medication safety than cefuroxime.